• DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

    来源: Nasdaq GlobeNewswire / 14 2月 2022 16:30:00   America/New_York

    Montrouge, France, February 14, 2022

    DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

    DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18th at 8:40 am ET.

    A webcast of the presentation will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/

    A replay of the presentation will also be available on DBV Technologies’ website after the event.

    About DBV Technologies
    DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

    Investor Contact
    Anne Pollak
    DBV Technologies
    +1 857-529-2363
    anne.pollak@dbv-technologies.com

    Media Contact
    Angela Marcucci
    DBV Technologies
    +1 646-842-2393

    angela.marcucci@dbv-technologies.com

    Attachment


分享